• Alterity Therapeutics reported positive FDA feedback from a second Type C meeting on its planned Phase 3 program for ATH434 in multiple system atrophy.
• Regulators backed Alterity’s chemistry, manufacturing, and control plans, supporting readiness to start Phase 3 while manufacturing scale-up continues.
• No clinical results were presented in this update.
• Alterity kept its End-of-Phase 2 meeting timeline unchanged, targeting mid-2026 to finalize Phase 3 plans with FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-013364), on April 27, 2026, and is solely responsible for the information contained therein.